Adagen Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The adagen market size has grown strongly in recent years. It will grow from $0.09 million in 2025 to $0.1 million in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to lack of alternative therapies for ada scid, early success of enzyme replacement therapy, improved patient survival rates, orphan drug regulatory incentives, adoption by specialty immunology centers.

The adagen market size is expected to see strong growth in the next few years. It will grow to $0.13 million in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in genetic screening, rising rare disease awareness, expansion of specialty immunology clinics, supportive reimbursement frameworks, increased investment in orphan drugs. Major trends in the forecast period include sustained use in rare immunodeficiency disorders, growing emphasis on enzyme replacement therapies, increasing long term scid patient management, rising integration of supportive immunology care, enhanced focus on pediatric rare disease treatment.

The growing adoption of precision medicine is expected to drive the growth of the Adagen market in the coming years. Precision medicine is an advanced healthcare approach that customizes medical treatments and preventive strategies based on individual patient characteristics. The increased adoption of precision medicine is supported by advancements in genomic technologies, wider availability of biomarkers, integration of artificial intelligence in healthcare, and rising demand for targeted therapies aligned with patients’ genetic profiles. Adagen supports precision medicine by providing a targeted enzyme replacement therapy specifically developed for patients with severe combined immunodeficiency (SCID) resulting from adenosine deaminase deficiency, highlighting the value of personalized treatments for rare genetic disorders. For example, in February 2024, according to data from the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable increase compared to six approvals in 2022. As a result, the expanding adoption of precision medicine is fueling growth in the Adagen market.

Rising healthcare expenditure is also expected to propel the Adagen market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, and healthcare infrastructure by individuals, governments, and organizations. The increase in healthcare spending is driven by factors such as advancements in medical technology, an aging population, higher prevalence of chronic diseases, demand for specialized therapies, and overall medical cost inflation. Adagen contributes to healthcare expenditure by offering specialized enzyme replacement therapy for rare genetic conditions, leading to greater investment in research, patient care, and improved access to treatments for disorders such as severe combined immunodeficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. Total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Therefore, increasing healthcare expenditure is supporting the growth of the Adagen market.

The rising diagnosis of rare diseases is further expected to support the expansion of the Adagen market. Rare diseases are conditions that affect fewer than one in 2,000 individuals and are often genetic in nature, with significant health consequences. The growing identification of rare diseases is driven by improvements in genetic testing technologies, greater awareness among healthcare professionals, enhanced healthcare infrastructure, and expanded international collaboration in rare disease research. Adagen plays a role in addressing the growing diagnosis of rare diseases by providing targeted enzyme replacement therapy for severe combined immunodeficiency, thereby increasing awareness, encouraging early diagnosis, and supporting broader research into rare genetic disorders and their treatment options. For example, in February 2024, according to Genetic Alliance UK, a UK-based national alliance of organizations, rare conditions affect more than 3.5 million people in the UK, with one in 17 individuals experiencing a rare condition at some point in their lives. Of the approximately 7,000 identified rare diseases, around 70% affect children, and more than 30% of affected children die before the age of five due to the severity of these conditions. Consequently, the increasing diagnosis of rare diseases is driving growth in the Adagen market.

Major companies operating in the adagen market are Leadiant Biosciences Inc.

North America was the largest region in the adagen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adagen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adagen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have had a limited yet notable impact on the adagen market by increasing costs for imported enzyme production materials and cold chain logistics. These effects are most significant in europe and asia pacific regions dependent on international supply. Higher tariffs can influence pricing stability for rare disease therapies. However, they are also encouraging regional production partnerships. This improves long term supply reliability for critical enzyme treatments.

The adagen market research report is one of a series of new reports that provides adagen market statistics, including adagen industry global market size, regional shares, competitors with a adagen market share, detailed adagen market segments, market trends and opportunities, and any further data you may need to thrive in the adagen industry. This adagen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adagen is the brand name for pegademase bovine, an enzyme replacement therapy used to treat severe combined immunodeficiency (SCID) resulting from adenosine deaminase deficiency. It supports immune function in individuals with SCID by replenishing the missing enzyme required for normal immune system development, thereby helping to lower the risk of life-threatening infections.

The main product forms of Adagen include pre-filled and vial presentations. Pre-filled formulations are supplied in ready-to-use syringes or devices, offering convenience and accurate dosing for patients. Adagen is primarily used to treat clinical conditions such as severe combined immunodeficiency (SCID) and other rare genetic disorders, and it is utilized across settings including hospitals and healthcare institutions, specialty clinics, home healthcare services, and research institutions.

The adagen market consists of sales of single-use vials and ready-to-use syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.